Screener
InMed Pharmaceuticals INM Q2 2026 Annual earnings
Reported September 23, 2026 · After market close
Revenue$2.1BIn line
EPS-$1.43Beat by $93.01
Revenue estimate$2.1B
EPS estimate-$94.44
Next report
Nov 5, 2026 (In 3 days)Revenue estimate$300.0K
EPS estimate-$94.44
Versus estimates
Revenue
Diluted EPS
Q2 2026-$1.43Beat by $93.01
Q1 2026-$0.69Beat by $93.75Q4 2025-$0.51Q3 2025-$0.44Q2 2025-$3.80Q1 2025-$1.94FAQ
- When did InMed Pharmaceuticals report Q2 2026 earnings?
- InMed Pharmaceuticals (INM) reported Q2 2026 earnings on September 23, 2026 after market close.
- What were InMed Pharmaceuticals's Q2 2026 revenue and EPS?
- InMed Pharmaceuticals reported revenue of $2.1B and eps of $-1.43 for Q2 2026.
- Did InMed Pharmaceuticals beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $2.1B by -. EPS beat the consensus estimate of $-94.44 by $93.01.
- How did InMed Pharmaceuticals's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 115691.6% from $1.8M a year earlier and eps grew 62.4% from $-3.80.
- Where can I find InMed Pharmaceuticals's Q2 2026 SEC filings?
- You can read the 10-K periodic report (0001213900-26-098419) directly on SEC EDGAR. The filing index links above go to sec.gov.
